Page 17 - Read Online

Calais da Silva et al. Systemic humoral responses during BCG treatment

proteins. J Immunol 2004;172:5467-77. 37. Yamada H, Odonnell MA, Matsumoto T, Luo Y. Interferon-gamma up-
34. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in regulates toll-like receptor 4 and cooperates with lipopolysaccharide
BCG immunotherapy for superficial bladder cancer. Br J Cancer to produce macrophage-derived chemokine and interferon-gamma
2004;91:607-12. inducible protein-10 in human bladder cancer cell line RT4. J Urol
35. Bevers RF, de Boer EC, Kurth KH, Schamhart DH. BCG-induced 2005;174:1119-23.
interleukin-6 upregulation and BCG internalization in well and poorly 38. Jackson AM, Alexandrov AB, Prescott S, James K. Production of
differentiated human bladder cancer cell lines. Eur Cytokine Netw urinary tumour necrosis factors and soluble tumour necrosis factor
1998;9:181-6. receptors in bladder cancer patients after bacillus Calmette-Guérin
36. Luo Y, Han R, Evanoff DP, Chen X. Interleukin-10 inhibits immunotherapy. Cancer Immunol Immunother 1995;40:119-24.
Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced 39. Ryk C, Steineck G, Wiklund NP, Nyberg T, de Verdier PJ. The (CCTTT)
macrophage cytotoxicity against bladder cancer cells. Clin Exp n microsatellite polymorphism in the nitric oxide synthase 2 gene may
Immunol 2010;160:359-68. influence bladder cancer pathogenesis. J Urol 2010;184:2150-7.

126 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ July 14, 2017